Photos: Shutterstock

In­ver­sa­go was work­ing to­ward a po­ten­tial 2024 IPO, but No­vo’s in­ter­est won out. CB1 biotechs hope to ride the wave

Be­fore We­govy drug­mak­er No­vo Nordisk swept in to buy In­ver­sa­go Phar­ma for up to $1.075 bil­lion ear­li­er this month, the small Cana­di­an biotech had been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.